Search Results - "Massey, Dan"

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations by SEQUIST, Lecia V, YANG, James Chih-Hsin, SU, Wu-Chou, BENNOUNA, Jaafar, KATO, Terufumi, GORBUNOVA, Vera, KI HYEONG LEE, SHAH, Riyaz, MASSEY, Dan, ZAZULINA, Victoria, SHAHIDI, Mehdi, SCHULER, Martin, YAMAMOTO, Nobuyuki, O'BYRNE, Kenneth, HIRSH, Vera, MOK, Tony, GEATER, Sarayut Lucien, ORLOV, Sergey, TSAI, Chun-Ming, BOYER, Michael

“…The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly…”
Get full text

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial by Wu, Yi-Long, Prof, Zhou, Caicun, Prof, Hu, Cheng-Ping, Prof, Feng, Jifeng, Prof, Lu, Shun, Prof, Huang, Yunchao, Prof, Li, Wei, Prof, Hou, Mei, Prof, Shi, Jian Hua, Prof, Lee, Kye Young, Prof, Xu, Chong-Rui, MD, Massey, Dan, MSc, Kim, Miyoung, MD, Shi, Yang, MD, Geater, Sarayut L, MD

“…Summary Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free survival compared with pemetrexed and cisplatin for first-line…”
Get full text

Characterization of gut microbiomes of household pets in the United States using a direct-to-consumer approach by Jha, Aashish R, Shmalberg, Justin, Tanprasertsuk, Jirayu, Perry, LeeAnn, Massey, Dan, Honaker, Ryan W

“…The role of gut microbiomes as important regulators of mammalian health is increasingly recognized, although feline and canine gut microbiomes remain poorly…”
Get full text

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations by YANG, James Chih-Hsin, HIRSH, Vera, PALMER, Michael, SEQUIST, Lecia V, SCHULER, Martin, YAMAMOTO, Nobuyuki, O'BYRNE, Kenneth J, MOK, Tony S. K, ZAZULINA, Victoria, SHAHIDI, Mehdi, LUNGERSHAUSEN, Juliane, MASSEY, Dan

“…Patient-reported symptoms and health-related quality of life (QoL) benefits were investigated in a randomized, phase III trial of afatinib or…”
Get full text

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3 by Kato, Terufumi, Yoshioka, Hiroshige, Okamoto, Isamu, Yokoyama, Akira, Hida, Toyoaki, Seto, Takashi, Kiura, Katsuyuki, Massey, Dan, Seki, Yoko, Yamamoto, Nobuyuki

“…In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma…”
Get full text

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial by Barone, Paolo, Prof, Poewe, Werner, Prof, Albrecht, Stefan, MD, Debieuvre, Catherine, PharmD, Massey, Dan, MSc, Rascol, Olivier, Prof, Tolosa, Eduardo, Prof, Weintraub, Daniel, Prof

“…Summary Background Depression is common in patients with Parkinson's disease, but evidence on the efficacy of antidepressants in this population is lacking…”
Get full text

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 by Wu, Yi-Long, Sequist, Lecia V, Hu, Cheng-Ping, Feng, Jifeng, Lu, Shun, Huang, Yunchao, Li, Wei, Hou, Mei, Schuler, Martin, Mok, Tony, Yamamoto, Nobuyuki, O'Byrne, Kenneth, Hirsh, Vera, Gibson, Neil, Massey, Dan, Kim, Miyoung, Yang, James Chih-Hsin

“…Background: In the Phase III LUX-Lung 3/6 (LL3/LL6) trials in epidermal growth factor receptor ( EGFR ) mutation-positive lung adenocarcinoma patients, we…”
Get full text

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease by Schmid, Peter, Cortes, Javier, Joaquim, Ana, Jañez, Noelia Martínez, Morales, Serafín, Díaz-Redondo, Tamara, Blau, Sibel, Neven, Patrick, Lemieux, Julie, García-Sáenz, José Ángel, Hart, Lowell, Biyukov, Tsvetan, Baktash, Navid, Massey, Dan, Burris, 3rd, Howard A, Rugo, Hope S

“…Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity and restoring inhibition of AKT by…”
Get full text

G-RCA: A Generic Root Cause Analysis Platform for Service Quality Management in Large IP Networks by Yan, He, Breslau, Lee, Ge, Zihui, Massey, Dan, Pei, Dan, Yates, Jennifer

“…An increasingly diverse set of applications, such as Internet games, streaming videos, e-commerce, online banking, and even mission-critical emergency call…”
Get full text

Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease by Tang, Yan, Massey, Dan, Zhong, Nan-shan

“…A pharmacokinetic study in an Asian population showed that tiotropium 5 µg via Respimat leads to the same plasma levels compared to 18 µg via HandiHaler. The…”
Get full text

Deploying and Monitoring DNS Security (DNSSEC) by Osterweil, E., Massey, D., Lixia Zhang

“…SecSpider is a DNSSEC monitoring system that helps identify operational errors in the DNSSEC deployment and discover unforeseen obstacles. It collects,…”
Get full text

Empagliflozin in Patients with Chronic Kidney Disease by Herrington, William G, Staplin, Natalie, Wanner, Christoph, Green, Jennifer B, Hauske, Sibylle J, Emberson, Jonathan R, Preiss, David, Judge, Parminder, Mayne, Kaitlin J, Ng, Sarah Y A, Sammons, Emily, Zhu, Doreen, Hill, Michael, Stevens, Will, Wallendszus, Karl, Brenner, Susanne, Cheung, Alfred K, Liu, Zhi-Hong, Li, Jing, Hooi, Lai Seong, Liu, Wen, Kadowaki, Takashi, Nangaku, Masaomi, Levin, Adeera, Cherney, David, Maggioni, Aldo P, Pontremoli, Roberto, Deo, Rajat, Goto, Shinya, Rossello, Xavier, Tuttle, Katherine R, Steubl, Dominik, Petrini, Michaela, Massey, Dan, Eilbracht, Jens, Brueckmann, Martina, Landray, Martin J, Baigent, Colin, Haynes, Richard

“…In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes…”
Get full text

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases by Schuler, Martin, Wu, Yi-Long, Hirsh, Vera, O'Byrne, Kenneth, Yamamoto, Nobuyuki, Mok, Tony, Popat, Sanjay, Sequist, Lecia V, Massey, Dan, Zazulina, Victoria, Yang, James C-H

“…Metastatic spread to the brain is common in patients with non-small cell lung cancer (NSCLC), but these patients are generally excluded from prospective…”
Get more information

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations by Sequist, Lecia V, Yang, James Chih-Hsin, Yamamoto, Nobuyuki, O'Byrne, Kenneth, Hirsh, Vera, Mok, Tony, Geater, Sarayut Lucien, Orlov, Sergey, Tsai, Chun-Ming, Boyer, Michael, Su, Wu-Chou, Bennouna, Jaafar, Kato, Terufumi, Gorbunova, Vera, Lee, Ki Hyeong, Shah, Riyaz, Massey, Dan, Zazulina, Victoria, Shahidi, Mehdi, Schuler, Martin

“…The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly…”
Get full text

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial by Park, Keunchil, Prof, Tan, Eng-Huat, MD, O'Byrne, Ken, Prof, Zhang, Li, Prof, Boyer, Michael, Prof, Mok, Tony, Prof, Hirsh, Vera, Prof, Yang, James Chih-Hsin, Prof, Lee, Ki Hyeong, MD, Lu, Shun, Prof, Shi, Yuankai, MD, Kim, Sang-We, MD, Laskin, Janessa, MD, Kim, Dong-Wan, Prof, Arvis, Catherine Dubos, MD, Kölbeck, Karl, MD, Laurie, Scott A, MD, Tsai, Chun-Ming, Prof, Shahidi, Mehdi, MD, Kim, Miyoung, MD, Massey, Dan, PhD, Zazulina, Victoria, MD, Paz-Ares, Luis, MD

“…Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line…”
Get full text

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials by Yang, James Chih-Hsin, Prof, Wu, Yi-Long, Prof, Schuler, Martin, Prof, Sebastian, Martin, MD, Popat, Sanjay, FRCP, Yamamoto, Nobuyuki, Prof, Zhou, Caicun, Prof, Hu, Cheng-Ping, Prof, O'Byrne, Kenneth, Prof, Feng, Jifeng, Prof, Lu, Shun, Prof, Huang, Yunchao, Prof, Geater, Sarayut L, MD, Lee, Kye Young, Prof, Tsai, Chun-Ming, Prof, Gorbunova, Vera, Prof, Hirsh, Vera, Prof, Bennouna, Jaafar, Prof, Orlov, Sergey, Prof, Mok, Tony, Prof, Boyer, Michael, Prof, Su, Wu-Chou, Prof, Lee, Ki Hyeong, Prof, Kato, Terufumi, MD, Massey, Dan, MSc, Shahidi, Mehdi, MD, Zazulina, Victoria, MD, Sequist, Lecia V, MD

“…Summary Background We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an…”
Get full text

Inferring the Origin of Routing Changes using Link Weights by Lad, M., Oliveira, R., Massey, D., Lixia Zhang

“…The global Internet routing infrastructure is a large and complex distributed system where routing changes occur constantly. Our objective in this paper is to…”
Get full text

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma by De Grève, Jacques, Moran, Teresa, Graas, Marie-Pascale, Galdermans, Daniella, Vuylsteke, Peter, Canon, Jean-Luc, Schallier, Denis, Decoster, Lore, Teugels, Erik, Massey, Dan, Chand, Vikram K, Vansteenkiste, Johan

“…Highlights • Afatinib monotherapy was active in NSCLC tumors with HER2 activating mutations. • Afatinib monotherapy was active in NSCLC tumors overexpressing…”
Get full text

ROVER: Route Origin Verification Using DNS by Gersch, Joseph, Massey, Dan

“…The Border Gateway Protocol (BGP) is a critical component of the global internet infrastructure. Unfortunately BGP routing was designed with limited regard for…”
Get full text

XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement by Schmid, Peter, Rugo, Hope S., Cortes, Javier, Huang, Chin-Lun, Crossley, Kate, Massey, Dan, Burris, Howard A.

“…Abstract only TPS1103 Background: The mTOR inhibitor Ev, combined with Ex, is a mainstay in the treatment of post-menopausal women with advanced HR+/HER2- BC…”
Get full text